Articles

California OKs Anthem rate hike after controversy

The California Department of Insurance said Wednesday it approved a rate increase averaging about 14 percent for Anthem Blue
Cross customers. The department also OK’d a nearly 19-percent increase for Blue Shield of California.

Read More

Estimate puts Indiana health overhaul costs at $3.1B

Family and Social Services Administration Secretary Anne Murphy and acting Insurance Commissioner Stephen Robertson have sent
Gov. Mitch Daniels a letter that now estimates the overhaul will cost Indiana $235 million more than the previous estimate
in May.

Read More

VA hospital, health-info exchange enter pilot project

The Roudebush Veterans Affairs Medical Center and the Indiana Health Information Exchange are going to work to make
their medical record systems talk to each other in a pilot project spearheaded by the U.S. Department of Veterans Affairs.

Read More

Lilly woes take notch out of debt rating

Even with debt levels at Eli Lilly and Co. at paltry lows, a string of bad news finally forced Standard & Poor’s
to lower
its rating on the company’s senior unsecured debt. But the New York-based agency said it believes the Indianapolis-based
drugmaker will eventually break its string of bad luck on developing new products.

Read More

Health costs surge despite weak inflation

Ben Bernanke may be worried about deflation in the economy, but there’s certainly no chance of it in health care and
insurance. Employers’ health plan premiums surged another 8 percent this year, according to results from a massive survey
by Indianapolis-based United Benefit Advisors.

Read More

Lilly wins temporary ban on sales of Strattera copies

The invalidation of Lilly’s Strattera patent opened the door for as many as 10 companies to sell generic versions of the drug,
which generated U.S. sales of $445.6 million last year as a treatment for attention deficit hyperactivity disorder.

Read More

Bad news piles up for Lilly

What a tough week for Lilly. On Aug. 12, a judge struck down the Indianapolis-based drugmaker’s U.S. patent on Strattera,
which might cost the company about $450 million in annual revenue. Then, five days later, Lilly halted clinical trials on
one
of its experimental Alzheimer’s medicines, because patients did worse on the drug than on a placebo.

Read More

Q&A

Dr. Kevin Macadaeg, vice president of the Indiana Spine Group, talked about his physician
group's decision to build a 60,000-square-foot medical office and "bioskills" lab in Carmel next year, as well
as the group's commitment to grow independently in the face of pressures from hospital acquisitions and health reform.

Read More

Expanding hospitals target Bloomington

Monroe Hospital in Bloomington is the latest target in the statewide buildup by hospital systems. St. Vincent Health, St.
Francis and at least one other system have all had talks in the past month with Monroe.

Read More

Visteon ordered to reinstate health care to retirees

The mandate from a U.S. bankruptcy judge will supply retroactive benefits to more than 6,000 Visteon Corp. retirees who lost
insurance coverage after
the
Michigan-based auto-parts maker filed for bankruptcy in 2009, including 2,100 workers in Indiana.

Read More